Payment overview · 2025
General Payments
$3,605.30
142 reported records · 25 companies
Healthcare provider profile · identity verified
Thomas J Malvar, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEW CASTLE, PA · NPI 1851382626
Verified facts
What the public records show
CMS Open Payments records show Thomas J Malvar, MD received $3,605.30 in general payments during 2025 across 142 reported records.
Amgen Inc. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Farxiga, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Auvelity by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $410.79 | 11.4% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $370.55 | 10.3% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $338.11 | 9.4% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $304.67 | 8.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $237.84 | 6.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $235.20 | 6.5% | 13 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $232.77 | 6.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $217.85 | 6.0% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $214.55 | 6.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.50 | 5.0% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $144.55 | 4.0% | 9 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.28 | 3.9% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $130.82 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.04 | 3.4% | 6 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.00 | 2.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.54 | 1.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.58 | 1.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.36 | 1.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.73 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.03 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.18 | 0.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.84 | 0.4% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.53 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.15 | 0.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.84 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,574.03 | 140 |
| Education | $31.27 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $348.67 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $311.31 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $304.67 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $283.38 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $264.88 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $237.84 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $232.77 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $186.31 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $179.23 | 10 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $166.19 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $145.91 | 7 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $145.91 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $144.56 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $144.55 | 9 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $141.28 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $128.32 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $121.04 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.09 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.18 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.21 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.34 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.58 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 322 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 24 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
322 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
322 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 730 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 716 | 150 |
| Simvastatin | Simvastatin | 624 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 449 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 385 | 89 |
| Metformin Hcl | Metformin Hcl | 369 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 339 | 76 |
| Lisinopril | Lisinopril | 338 | 73 |
| Eliquis | Apixaban | 322 | 34 |
| Gabapentin | Gabapentin | 296 | 45 |
| Omeprazole | Omeprazole | 276 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 253 | 33 |
| Potassium Chloride | Potassium Chloride | 249 | 47 |
| Furosemide | Furosemide | 241 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 46 |
| Losartan Potassium | Losartan Potassium | 193 | 45 |
| Donepezil Hcl | Donepezil Hcl | 182 | 28 |
| Alprazolam | Alprazolam | 178 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 38 |
| Famotidine | Famotidine | 169 | 60 |
| Tramadol Hcl | Tramadol Hcl | 167 | 38 |
| Glipizide | Glipizide | 162 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 23 |
| Sertraline Hcl | Sertraline Hcl | 132 | 26 |
| Memantine Hcl | Memantine Hcl | 129 | 15 |
| Farxiga | Dapagliflozin Propanediol | 128 | 24 |
| Carvedilol | Carvedilol | 127 | 20 |
| Synthroid | Levothyroxine Sodium | 127 | 23 |
| Atenolol | Atenolol | 126 | 30 |
| Allopurinol | Allopurinol | 124 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 13 |
| Montelukast Sodium | Montelukast Sodium | 101 | 18 |
| Alendronate Sodium | Alendronate Sodium | 100 | 21 |
| Azithromycin | Azithromycin | 100 | 85 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 20 |
| Ozempic | Semaglutide | 83 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 82 | 60 |
| Xarelto | Rivaroxaban | 78 | 15 |
| Lorazepam | Lorazepam | 77 | 14 |
| Jardiance | Empagliflozin | 73 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | suppressed |
| Lamotrigine | Lamotrigine | 69 | suppressed |
| Methylprednisolone | Methylprednisolone | 68 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 49 |
| Ezetimibe | Ezetimibe | 64 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | suppressed |
| Prednisone | Prednisone | 62 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 55 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Meloxicam | Meloxicam | 49 | 13 |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Naproxen | Naproxen | 44 | 16 |
| Valsartan | Valsartan | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 38 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 11 |
| Baclofen | Baclofen | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 20 |
| Spironolactone | Spironolactone | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 26 |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Repaglinide | Repaglinide | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 20 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 17 |
| Ondansetron Odt | Ondansetron | 31 | 21 |
| Colchicine | Colchicine | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 23 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nystatin | Nystatin | 21 | 16 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Fluconazole | Fluconazole | 19 | 15 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 12 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tetracycline Hcl | Tetracycline Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Monoject Insulin Safety Syrng | Syringe With Needle, Insulin | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,605.30 · 142 records | Amgen Inc. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JASCAYD, Kerendia, LOREEV XR, MOUNJARO, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, TERIPARATIDE, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error